CGRP vs Neuropeptide S — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide produced by alternative splicing of the calcitonin gene in neurons. It is the most abundant neuropeptide in the sensory nervous system, expressed in trigeminal ganglion neurons and released from perivascular n...
Calculate CGRP dose →Neuropeptide S (NPS) is a 20-amino acid peptide discovered in 2004 that acts on the NPS receptor (NPSR1), a Gq/Gs-coupled GPCR with highest expression in amygdala, hypothalamus, and brainstem arousal centers. NPS produces a distinctive combination of simultaneous wakefulness prom...
Calculate Neuropeptide S dose →| Parameter | CGRP | Neuropeptide S |
|---|---|---|
| Category | Neuropeptide | Neuropeptide |
| Research | FDA Approved (Anti-CGRP antibodies) | Preclinical |
| Half-Life | ~7-10 min (plasma; native) | Short (minutes, CNS) |
| Typical Dose | Anti-CGRP mAbs: 70-240 mg SC monthly or quarterly | 0.1-10 nmol (ICV, animal) |
| Frequency | Monthly or quarterly (approved antibodies) | Variable |
| Route | Endogenous; IV/SC (research) | Intracerebroventricular (animal research) |
| FDA Status | Anti-CGRP antibodies approved (erenumab, fremanezumab, galcanezumab, eptinezumab) | Not approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.